Stock 6417 SANKYO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Sankyo Co., Ltd.

Equities

6417

JP3326410002

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-06-24 EDT 		5-day change 1st Jan Change
1,690 JPY -0.97% Intraday chart for Sankyo Co., Ltd. +1.35% +2.79%
05-09 Sankyo Co., Ltd. Proposes Dividend for the Year Ending March 31, 2024, Payable on June 28, 2024; Provides Earnings Guidance for the Year Ended March 31, 2025 CI
05-09 Sankyo Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sankyo : Supplementary Explanation Regarding Item to Be Proposed at the 59th Ordinary General Meeting of Shareholders
PU
Sankyo : Notice Concerning Dividends of Surplus
PU
Sankyo : Notice Concerning the Formulation of the Mid-term Business Plan
PU
Sankyo Co., Ltd. Proposes Dividend for the Year Ending March 31, 2024, Payable on June 28, 2024; Provides Earnings Guidance for the Year Ended March 31, 2025
CI
Sankyo Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025
CI
AstraZeneca makes progress with Truqap and Enhertu cancer treatments
AN
AstraZeneca upbeat as cancer drugs underpin sales growth
AN
AstraZeneca hails neurological data for Ultomiris, Soliris
AN
AstraZeneca's, Daiichi's Enhertu receives US FDA approval
AN
AstraZeneca, Daiichi make US progress with licence approvals
AN
AstraZeneca and Daiichi make US progress with latest licence approvals
AN
Final dividend
FA
Sankyo Exhausts Buyback Program After Repurchasing 50 Million Shares for 68.77 Billion Yen
MT
Tranche Update on Sankyo Co., Ltd.'s Equity Buyback Plan announced on November 7, 2023.
CI
Sankyo Co., Ltd.'s Equity Buyback announced on November 7, 2023, has closed with 50,000,000 shares, representing 19.32% for ¥68,767.93 million.
CI
AstraZeneca's breast cancer treatment blocked for NHS use in England
AN
AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment
AN
Split: 5 of 1
FA
Nikkei extends record rally on pharma boost
RE
Nikkei hits record high as index heavyweights advance
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6417 Stock
  4. News Sankyo Co., Ltd.